Over the last years, the decreased costs and enhanced accessibility to large genome-wide
association studies datasets have laid the foundations for the development of polygenic risk …

Advances in genomics have enabled the development of polygenic scores (PGS),
sometimes called polygenic risk scores, in the context of multifactorial diseases and …

Since their first appearance in the context of schizophrenia and bipolar disorder in 2009,
polygenic risk scores (PRSs) have been described for a large number of common complex …

Chronic illnesses are a major threat to global population health through the lifespan into
older age. Despite world-wide public health goals, there has been a steady increase in …

Background and purpose The response to cluster headache treatments has a high
interindividual variation. To date, treatment response has only been assessed by a …

Pharmacogenomics is the examination of how genetic variation influences drug metabolism
and response, in terms of both efficacy and safety. In cardiovascular disease, patient …

Abstract Background Major Depressive Disorder (MDD) is a heterogenous brain disorder,
with potentially multiple psychosocial and biological disease mechanisms. This is also a …

Research has suggested that mental illness may be a risk factor for, as well as a sequela of,
experiencing intimate partner violence (IPV). The association between IPV and mental …

Using Swedish registers, we examine whether the prescription of and the response to
antidepressants (AD), mood stabilizers (MS), and antipsychotics (AP) in the treatment of …

Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment
with antidepressant drugs (ATD), which target monoamine neurotransmitters including …